Pharmacokinetics and Safety of Eszopiclone in Healthy Chinese VolunteersData from a Single-center, Open-label, Single and Multiple Dose, Randomized, Crossover Pharmacokinetic Study of Eszopiclone under Fasting Conditions
received 28 January 2012
accepted 05 September 2012
04 October 2012 (eFirst)
The main objective of this study was to investigate the pharmacokinetic characters of eszopiclone (CAS: 138729-47-2) after single and multiple-dose oral administration in healthy adult Chinese volunteers.
In single-dose study, 12 subjects were given oral administrations of 1.5, 3 and 6 mg eszopiclone in an open-label, randomized, crossover fashion. In multiple-dose study, 8 subjects were given 3 mg eszopiclone once daily consecutively for 7 days. Blood samples were collected over 24 h and plasma eszopiclone were determined using a validated liquid chromatography/mass spectrometry (LC/MS/MS) assay. The safety and tolerability of eszopiclone was evaluated by adverse events recording, physical examination, laboratory testing, vital signs, and 12-lead ECG findings.
The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0–24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h. After multiple-dose administration, the steady-state levels of eszopiclone were achieved by the 4th day, and the main pharmacokinetic parameters were Css_max at 33.43±5.63 ng/ml and AUCss (0–24) at 263.30±51.21 ng*h/ml. The most common adverse event was bitter or abnormal taste. All the adverse events were judged as mild to moderate and resolved without any medication.
The pharmacokinetic character of eszopiclone is linear and dose-proportional over the range of 1.5–6 mg. The systemic exposure does not accumulate with once-daily administrations. Eszopiclone appears to have good safety and is well tolerated.
- 1 Hair PI, McCormack PL, Curran MP. Eszopiclone: a review of its use in the treatment of insomnia. Drugs 2008; 68 (10) 1415-1434
- 2 Zammit GK, McNabb LJ, Caron J et al. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004; 20 (12) 1979-1991
- 3 Roth T, Walsh JK, Krystal A et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005; 6 (06) 487-495
- 4 Melton ST, Wood JM, Kirkwood CK. Eszopiclone for insomnia. Ann Pharmacother 2005; 39 (10) 1659-1666
- 5 Halas CJ. Eszopiclone. Am J Health Syst Pharm 2006; 63 (01) 41-48
- 6 Ancoli-Israel S, Krystal AD, McCall WV et al. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep 2010; 33 (02) 225-234
- 7 U.S. Department of Health and Human Services, Food and drug administration Center for Drug Evaluation and Research (CDER) Guidance for Industry: Bioanalytical Method Validation; May 2001
- 8 Meng M, Rohde L, Cápka V et al. Fast chiral chromatographic method development and validation for the quantitation of eszopiclone in human plasma using LC/MS/MS. J Pharm Biomed Anal 2010; 53 (04) 973-982
- 9 Smith BP, Vandenhende FR, DeSante KA et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res 2000; 17 (10) 1278-1283
- 10 Food and Drug Administration/Center for Drug Evaluation and Research (CDER) . Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. Washington, DC: Food and Drug Administration; March 2003
- 11 Drover DR. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives-Zaleplon, zolpidem and zopiclone. Clin Pharmacokinet 2004; 43 (04) 227-238
- 12 Laustsen G. Eszopiclone (lunesta) for treatment of insomnia. Nurse Practitioner 2005; 30 (09) 67-68
- 13 Lunesta (eszopiclone) tablets package insert. Marlborough, MA: Sepracor Inc; 2005